Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02538341 · ClinicalTrials.gov registry record · Phase 2
Safety and Effectiveness of Live Zoster Vaccine in Anti-Tumor Necrosis Factor (TNF) Users (VERVE Trial)
A Phase 2 study, sponsored by University of Alabama at Birmingham.
- Completed
- Registry status
- Phase 2
- Development phase
- 617
- Enrollment target
NCT02538341: Completed Phase 2 study, sponsored by University of Alabama at Birmingham.
NCT02538341 is a Phase 2 study that has completed, run by University of Alabama at Birmingham. The registered enrollment target is 617 participants, above the 133-participant average among 30,622 other Phase 2 trials with a reported enrollment target (364% higher). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT02538341, a Phase 2 study, has completed, sponsored by University of Alabama at Birmingham.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 617 participants
- Enrollment target
Study Summary
The VaricElla zosteR VaccinE (VERVE) trial evaluates the safety and effectiveness of the Herpes zoster (HZ) vaccine for shingles, Zostavax, in patients over 50 years old with arthritis and other diseases who are using anti-tumor necrosis factor (TNF) therapy and who have not previously received the vaccine.
Primary Outcome
Study protocol defined measure for immunogenicity samples.
Interventions
- DRUG Placebo
- BIOLOGICAL Herpes Zoster (HZ) Vaccine
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 617 participants |
| Start Date | 2016-05 |
| Est. Completion | 2020-12 |
| Phase | Phase 2 |
What the finished NCT02538341 record still lists
NCT02538341 is an interventional study that assigns participants to a tested intervention. The registered 617 participants enrollment target is mid-sized for trials with a published cap, above the 133-participant average among 30,622 other Phase 2 trials with a reported enrollment target (364% higher).
The record links to 0 conditions, and to 2 interventions - of which Placebo is the first listed.
NCT02538341 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT02538341 about?
NCT02538341 is a clinical study titled "Safety and Effectiveness of Live Zoster Vaccine in Anti-Tumor Necrosis Factor (TNF) Users (VERVE Trial)". The VaricElla zosteR VaccinE (VERVE) trial evaluates the safety and effectiveness of the Herpes zoster (HZ) vaccine for shingles, Zostavax, in patients over 50 years old with arthritis and other diseases who are using anti-tumor necrosis factor (TNF) therapy and who have not previously received the ...
What is the current status of trial NCT02538341?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 617 participants. The study started on 2016-05. Estimated completion is 2020-12.
What interventions are being tested in trial NCT02538341?
The interventions under investigation include: Placebo (DRUG), Herpes Zoster (HZ) Vaccine (BIOLOGICAL).
Who is sponsoring clinical trial NCT02538341?
This trial is sponsored by University of Alabama at Birmingham, which has 1,160 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT02538341's enrollment target sits among peer trials
617 53rd of 2000 higher than 1,948 of 2,000 other Phase 2 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 2 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT02610179 · 617 participants · NA
Strawberry Candy Twists as an Alternative Screen for Gestational Diabetes: A Prospective Trial
- NCT05672927 · 618 participants · Phase 4
Comparing Immune Response of 2 vs 3 HPV Doses (27-45 Years Old)
- NCT06220721 · 618 participants · NA
Reducing the Risk of Chronic Hypertension and Improving Vascular Function Following Preeclampsia
- NCT04813185 · 616 participants · NA
Preventing Retaliatory Gun Violence in Violently Injured Adults
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia